Genetics of autoinflammation instructs selective IL-1 targeting

Wang, 2023, Human IL-1 1R1 variant resistant to IL-1Ra inhibition leads to autoinflammation and enlightens new drug development, Immunity, 56, 1485, 10.1016/j.immuni.2023.05.014 Mantovani, 2019, Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity, Immunity, 50, 778, 10.1016/j.immuni.2019.03.012 Mantovani, 2023, Humoral Innate Immunity and Acute-Phase Proteins, N. Engl. J. Med., 388, 439, 10.1056/NEJMra2206346 Dinarello, 2011, Interleukin-1 in the pathogenesis and treatment of inflammatory diseases, Blood, 117, 3720, 10.1182/blood-2010-07-273417 Aksentijevich, 2009, An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist, N. Engl. J. Med., 360, 2426, 10.1056/NEJMoa0807865 Ridker, 2017, Effect of interleukin-1beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial, Lancet, 390, 1833, 10.1016/S0140-6736(17)32247-X Ridker, 2017, Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease, N. Engl. J. Med., 377, 1119, 10.1056/NEJMoa1707914 Lachmann, 2009, Use of canakinumab in the cryopyrin-associated periodic syndrome, N. Engl. J. Med., 360, 2416, 10.1056/NEJMoa0810787 Hoffman, 2004, Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist, Lancet, 364, 1779, 10.1016/S0140-6736(04)17401-1 Wu, 2018, IL-1 receptor antagonist controls transcriptional signature of inflammation in patients with metastatic breast cancer, Cancer Res., 78, 5243, 10.1158/0008-5472.CAN-18-0413